Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Human Umbilical Cord Mesenchymal Stem Cell Injection in ILD
NCT06534528Phase 1Not yet recruiting
- Sponsor
- Shanghai Life Science Technology
- Start
- Oct 2026
- Primary completion
- Oct 2027
- Modality
- Stem Cell Therapies
01
Overview
Phase 1, open-label, single-arm trial of human umbilical cord mesenchymal stem cells in interstitial lung disease (ILD), sponsored by Shanghai Life Science Technology. Primary endpoint: Maximum tolerated dose at 4 weeks. Planned start Oct 2026; status: not yet recruiting.
02
Drugs
human umbilical cord mesenchymal stem cells
03
Conditions
interstitial lung disease (ILD)
Beyond the preview
Go deeper on NCT06534528.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06534528.